The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Olema Oncology; Sanofi
OPERA-01: A randomized, open-label, phase 3 study of palazestrant (OP-1250) vs standard-of-care for patients with ER+, HER2- advanced or metastatic breast cancer after endocrine therapy and CDK4/6 inhibitors.
 
Joohyuk Sohn
Stock and Other Ownership Interests - Daiichi Sankyo (I)
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol Myerss guibb (Inst); Celcuity (Inst); Daiichi Sankyo (Inst); Dragonfly Therapeutics (Inst); Eikon (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Hanmi Pharm (Inst); HLB Life Science (Inst); ILDONG PHARMACEUTICAL (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Olema Oncology (Inst); Pfizer (Inst); Qurient (Inst); Roche (Inst); Samyang Holdings (Inst); Sanofi (Inst); Seagan (Inst); Sermonix Pharmaceuticals (Inst)
 
Barbara Pistilli
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/UCB Japan; Myriad Genetics; Novartis; PIERRE FABRE; Puma Biotechnology
Research Funding - AstraZeneca (Inst); DAIICHI-SANKYO (Inst); Gilead Sciences (Inst); Merus (Inst); Pfizer (Inst); Puma Biotechnology (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo Europe GmbH; MSD Oncology; Novartis; Pfizer; Pierre Fabre
 
Meritxell Bellet
Consulting or Advisory Role - Lilly; Novartis; Pfizer
Speakers' Bureau - Lilly; Novartis; Pfizer
 
Lucia Del Mastro
Honoraria - Lilly; MSD Oncology; Novartis; Roche
Consulting or Advisory Role - Agendia; AstraZeneca; Daiichi Sankyo; Eisai; Exact Sciences; Gilead Sciences; GlaxoSmithKline; Ipsen; Lilly; MSD; Novartis; Olema Oncology; Pfizer; Pierre Fabre; Roche; Seagen
Research Funding - AstraZeneca (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Gilead Sciences (Inst); Lilly (Inst); Novartis (Inst); Olema Oncology; Pfizer (Inst); Pierre Fabre (Inst); Roche (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Pfizer; Roche
 
Heather L. McArthur
Consulting or Advisory Role - AstraZeneca; Diichi-Sankyo; Lilly; Merck; Moderna Therapeutics; Pfizer
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Merck (Inst)
 
Jane Lowe Meisel
Honoraria - Medscape; Total Health Conferencing
Consulting or Advisory Role - AstraZeneca; Curio Science; GE Healthcare; Genentech; GlaxoSmithKline; Novartis; Olema Oncology; Pfizer; SeaGen
Research Funding - Olema Oncology (Inst); Pfizer; Seagen; Seagen (Inst); Sermonix Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Pfizer; Puma Biotechnology; Total Health Conferencing
 
Peter Schmid
Employment - Roche (I)
Honoraria - AstraZeneca; Bayer; Bayer; Boehringer Ingelheim; Celgene; Celgene; Eisai; Genentech (Inst); Gilead Sciences Hong Kong; Merck; Novartis; Oncogenex (Inst); Oncogenex (Inst); Pfizer; Puma Biotechnology; Roche; Sanofi; Stemline Therapeutics
Consulting or Advisory Role - AstraZeneca; Bayer; Boehringer Ingelheim; Celgene; Eisai; Genentech/Roche (I); Merck; Novartis; Pfizer; Puma Biotechnology
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Genentech (Inst); Medivation; Novartis (Inst); Oncogenex (Inst); Roche (Inst)
Travel, Accommodations, Expenses - ESMO; SABS
 
Rachel Wei
Employment - Olema Oncology
 
Arlene Chan
Honoraria - Eisai; Lilly
Travel, Accommodations, Expenses - Olema Oncology
 
Elisabeth de Kermadec
No Relationships to Disclose